Evidence map›Paper›PMID 38543788›Full record

ArticleViruses2024

Evaluation of the Polysaccharide "Immeran" Activity in

Liubov Viktorovna Generalova, Denis Pavlovich Laryushkin, Irina Anatolievna Leneva, Anna Valerievna Ivanina, Galina Vladimirovna Trunova, Sergei Vladimirovich Dolinnyi, Evgenii Aleksandrovich Generalov

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Anti-Inflammatory Effects ofInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Liubov Viktorovna GeneralovaFaculty of Medicine, Peoples' Friendship University of Russia (RUDN University), 117198 Moscow, Russia.
Denis Pavlovich LaryushkinFederal Research Center "Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences", Institute of Cell Biophysics of the Russian Academy of Sciences, 142290 Pushchino, Russia.ORCID 0000-0002-4903-5963
Irina Anatolievna LenevaMechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia.
Anna Valerievna IvaninaMechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia.
Galina Vladimirovna TrunovaFederal State Budgetary Institution National Medical Research Radiological Center (FSBI NMRRC) of the Ministry of Health of the Russian Federation, P.A. Hertsen Moscow, Oncology Research Institute, 125284 Moscow, Russia.
Sergei Vladimirovich DolinnyiFaculty of Medicine, Peoples' Friendship University of Russia (RUDN University), 117198 Moscow, Russia.
Evgenii Aleksandrovich GeneralovFaculty of Physics, Lomonosov Moscow State University, 119991 Moscow, Russia.ORCID 0000-0001-9135-6405
Peoples' Friendship University of Russia · RUResearch Institute of Vaccines and Sera. Mechnikov of the Russian Academy of Medical Sciences · RUInstitute of Cell Biophysics · RULomonosov Moscow State University · RUMinistry of Health of the Russian Federation · RU

Funding

ICB RAS No. 075-01512-22-02/004-00: 122112800049LLC SPC Gemma-B 0131032022
6 · The paper itself

Abstract

COVID-19 is a highly contagious respiratory disease with a high number of lethal cases in humans, which causes the need to search for new therapeutic agents. Polysaccharides could be one of the prospective types of molecules with a large variety of biological activities, especially antiviral. The aim of this work was to study the specific antiviral activity of the drug "Immeran" on a model of a new coronavirus infection SARS-CoV-2 in hamsters. Based on the second experiment, intraperitoneal treatment with the drug according to a treatment regimen in doses of 500 and 1000 μg/kg (administration after an hour, then once a day every other day, a total of 3 administrations) was effective, reliably suppressing the replication of the virus in the lungs and, at a dose of 1000 μg/kg, prevented weight loss in animals. In all cases, the treatment stimulated the formation of virus-neutralizing antibodies to the SARS-CoV-2 virus, which suggests that the drug possesses adjuvant properties.

Indexed as

COVID-19SARS-CoV-2AnimalsAntibodies, NeutralizingAntiviral AgentsCricetinaeDisease Models, AnimalHumansLungMesocricetusProspective StudiesAntibodies, NeutralizingAntiviral AgentsCOVID-19Immeranpolysacchariderespiratory diseaseSARS-CoV-2Solanum tuberosum L.Syrian hamsters

Identifiers

PMID38543788
PMCPMC10976179
OpenAlexW4392653557

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.